KEDI Global Obesity Care Industry Top 2+ Index

Q2 2026 earnings release is scheduled. Medium importance is estimated as earnings reports typically drive significant price movement. Analysts forecast EPS of ~$3.80-3.88 forecasted.

High importance is estimated due to the potential for significant market volatility following the report; Q2 2026 earnings release is scheduled.

Q2 2026 earnings and financial results for the first half of 2026 are scheduled to be announced on August 5, 2026; this scheduled event is estimated to have a low price impact (1-5%) scheduled.

Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; analysts forecast an EPS of approximately $5.57-$5.60. This event is assigned Medium importance as earnings reports typically cause price shifts of 5% or more scheduled.

Merck to release its second-quarter 2026 financial results on August 4, 2026, before the market opens; low impact expected.

Q2 2026 earnings release and conference call scheduled. Earnings reports typically have a high potential for price movement, justifying a High importance estimate.

AstraZeneca is scheduled to announce its H1 and Q2 2026 financial results on July 27, 2026. High importance is estimated due to the potential for a price impact of 10% or more from the semi-annual results, scheduled.

Novartis Q2 2026 financial results are scheduled to be released before the market opens on July 21, 2026, with analysts forecasting an EPS of around $2.15-$2.17. Earnings releases typically result in a price impact of approximately 5%. scheduled

The US Food and Drug Administration (FDA) granted traditional (full) approval for Fabhalta (iptacopan) on July 17, 2026, to slow kidney function decline in adults with primary IgA nephropathy (IgAN). This converts the accelerated approval granted in 2024.

Reported Q2 2026 earnings with adjusted EPS of $1.31, beating estimates of ~$1.28. Revenue was ~$12.5 billion, slightly missing estimates. The company raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. The stock rose over 11% in pre-market trading.

The U.S. FDA approved Lipfendra (enlicitide) on July 16, 2026, as the first once-daily oral PCSK9 inhibitor; high impact expected due to first-in-class status.

The European Commission granted marketing authorisation for the Wegovy pill (oral semaglutide 25 mg) for weight management on July 15, 2026; this first-in-class approval is estimated to have a high price impact (>10%).

AstraZeneca announced on July 14, 2026, that it entered into an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy, an oral lung cancer drug.

Merck's partner Kelun-Biotech announced on July 14, 2026, that a Phase 3 trial of sac-TMT with KEYTRUDA met its primary endpoint; medium impact expected as it strengthens the oncology pipeline.